Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Liposarcoma × cabazitaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 28 Neoplasm Metastasis 6 Recurrence 5 Breast Neoplasms 4 Prostate Cancer Metastatic 3 Neoplastic Cells, Circulating 3 Stomach Neoplasms 2 Ovarian Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Non-Small-Cell Lung 2 Brain Neoplasms 2 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Prostatic Neoplasms, Castration-Resistant 1 Prostate Cancer, Hereditary, 7 1 Penile Neoplasms 1 Nonseminomatous germ cell tumor 1 Metastatic Castration-resistant Prostate Cancer, MCRPC 1 Metastatic Castration-resistant Prostate Cancer 1 Metastatic Breast Cancer With Intracranial Metastases 1 Lung Neoplasms 1 Liposarcoma 1 Hormone-Resistant Prostate Cancer 1 Head and Neck Neoplasms 1 Glioblastoma 1 Diarrhea 1 Colorectal Neoplasms 1 Castrate-resistant Metastatic Prostate Cancer 1 Carcinoma, Squamous Cell 1 Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Trabectedin 5 Doxorubicin 5 pazopanib 3 Radiotherapy 3 Gemcitabine 3 ribociclib 2 palbociclib 2 brostallicin 2 Sunitinib 2 Imatinib Mesylate 2 Docetaxel 2 Dexamethasone 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 zimberelimab 1 temsirolimus 1 tanespimycin 1 talimogene laherparepvec 1 sotigalimab 1 soblidotin 1 sitravatinib 1 saracatinib 1 ridaforolimus 1 regorafenib 1 plitidepsin 1 perifosine 1 pembrolizumab 1 liposomal doxorubicin 1 exatecan 1 eribulin 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01913652 2021-09-14

Ph II Cabazitaxel DD Liposarcoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡